-
-
-
-
-
-
-
Cadence Pharmaceuticals, Inc. (CADX) Posts Q4 Loss of 25c/Share; Guides FY13 Revs
-
-
-
-
-
-
-
Collins Stewart Starts Cadence Pharma (CADX) at Buy; Ofirmev Sales Potential Underappreciated
-
-
1,207,998 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

